Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sucampo buys start-up Vtesse
by Ann M. Thayer
April 10, 2017
| A version of this story appeared in
Volume 95, Issue 15
Sucampo Pharmaceuticals will pay $200 million in stock and cash to acquire Vtesse, a privately held firm focused on rare diseases. Launched in January 2015, Vtesse was the first spin-off from the Pfizer-backed orphan drug accelerator Cydan Development. Vtesse’s lead product is VTS-270, a mixture of 2-hydroxypropyl-β-cyclodextrins in Phase II/III trials for the ultrarare genetic disorder Niemann-Pick disease type C1 (NPC). After the acquisition closes, Vtesse’s former owners intend to put a portion of proceeds, to be matched by Sucampo, into a new NPC-related research foundation.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter